Communicating potential risks in biotech requires a structured approach. Clearly identify each risk, quantify its impact on timelines and budget, present a robust mitigation plan, and frame the entire discussion around the business outcomes that matter most to senior decision makers.

To use storytelling effectively with biotech leadership, frame your presentation around real patient journeys, the future vision of your product's impact, and the scientific journey of discovery. This approach connects complex data to human outcomes, aligning your proposal with high-level strategic goals.

Improving a biotech team's investor pitches requires translating complex science into a clear business case. A focused program like Speaking Up: Presenting to Decision Makers® equips scientists to articulate value, build investor confidence, and secure funding by focusing on high-stakes executive communication.

Standard public speaking courses are insufficient for scientists presenting at regulatory meetings. You need specialized training in data defense, clarity under pressure, and managing challenging Q&A, which is precisely what next-level programs like Speaking Up: Presenting to Decision Makers® are designed to deliver.

Many presenters—especially technical experts—approach the C-Suite focused on their data and slide deck, but the reality is that the most challenging aspect of executive presentations isn't the content; it’s being savvy about managing a dynamic, and sometimes challenging, dialogue.

Effective training helps technical experts influence cross-functional teams by teaching them to translate complex data into business impact. They learn to adapt their message, understand diverse team priorities, and facilitate decision-making, which is precisely why we developed Speaking Up: Presenting to Decision Makers®.

Imagine trying to build a complex bridge without a blueprint or composing a symphony without capturing it on sheet music. It sounds absurd, yet every day in business, we attempt to communicate—in presentations, meetings, and even impromptu discussions—without a clear structure to make sure we’re being clear, concise, and compelling.

The return on investment (ROI) for quality, relevant communication training in biotech is measured in faster decision-making, fewer redundant meetings, and more successful investor and regulatory presentations. It directly impacts R&D pipeline velocity, capital allocation, and time-to-market, making it a strategic, not a "soft," skill investment.

To present complex scientific data to non-technical executives, reframe your findings around business outcomes. Focus on the "so what"—the impact on revenue, risk mitigation, or competitive advantage—rather than the intricate scientific process. A structured communication framework is essential for this translation.

Earlier in my career, I was a member of the executive team at a company that had just been acquired by a much, much larger competitor. When the suits came down from the new headquarters, the first leader we came in contact with literally said to us in a very smug, seemingly uncaring tone, “I recognize that you're going to need to marinate on this news for a bit, but you'll adjust.”